Skip to content

Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms

Intravenous Methylprednisolone Versus High Dose Oral Prednisolone for the Treatment of Infantile Spasms: a Randomized Open-labelled Trial

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03876444
Acronym
MPIV
Enrollment
128
Registered
2019-03-15
Start date
2019-04-01
Completion date
2022-10-31
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile Spasm

Keywords

Hypsarrythmia, Methylprednisolone, Prednisolone

Brief summary

Infantile Spasms (IS) are classically refractory to the usual antiepileptic drugs and often pose a therapeutic challenge. Since, there is associated significant morbidity, much effort has been directed over the past years to evaluate the role of various anticonvulsants in the management of IS. High dose oral prednisolone has been shown to cause early cessation of spasms and resolution of hypsarrythmia on Electroencephalogram. Recently, role of intravenous methylprednislone pulse therapy has been explored as one of the therapeutic modality in IS, in order to avoid the development of side-effects associated with prolonged oral steroid therapy and maintain long-term efficacy.However, there are no studies comparing iv methylprednisolone pulse therapy with high dose oral prednisolone..

Detailed description

Multiple studies have subsequently used higher dose of prednisolone in infantile spasms at the weight based dosing of 4-8 mg/kg/day with a maximum dose of 60mg/day. The results have shown high rates of clinical and elecroencephalographic remission with lower relapse rates.However, a major concern related to corticosteroids, especially in infants and children, is the possible development of side effects. The most frequent ones are excessive weight gain, hyperphagia, water retention with edema, cushingoid appearance, hypertension, behavioral disturbances, increased infection susceptibility, leukopenia, electrolyte disturbances, hyperglycemia, glycosuria, impaired glucose tolerance, frank diabetes and sleep disorders. Furthermore, long-term side effects such as hypothalamus-pituitary axis suppression, psychosis, osteoporosis, nephrocalcinosis, brain atrophy, cataracts and, in children, growth retardation, have also been reported. Recently, role of intravenous methylprednislone pulse therapy has been explored as one of the therapeutic modality in IS, in order to avoid the development of side-effects associated with prolonged oral steroid therapy and maintain long-term efficacy. There have been few studies on use of iv pulse methylprednisolone in IS with small sample size, showing to a rapid improvement in EEG & cessation of spasm in majority of the infants without significant adverse effects. Emerging evidence suggests that intravenous pulse methylprednisolone might have superior efficacy and better safety profile when compared to high dose oral prednisolone in treatment of IS. Hence, present study aims at comparing intravenous pulse methylprednisolone versus oral prednisolone in an open label, RCT for treatment of children with IS.

Interventions

Intravenous Methylprednisolone will be used in the intervention group

DRUGOral Pednisolone

Oral Prednisolone will be used in the Control Group

Sponsors

Suvasini Sharma
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Open label Randomized Control Trial

Eligibility

Sex/Gender
ALL
Age
4 Months to 30 Months
Healthy volunteers
No

Inclusion criteria

Newly diagnosed patients aged 4 - 30 months with epileptic spasms in clusters with electroencephalographic evidence of hypsarrhythmia or its variants with or without developmental delay -

Exclusion criteria

1. Children with recognized progressive neurological illness will be excluded. 2. Children with chronic renal, pulmonary, cardiac or hepatic dysfunction 3. Severe malnutrition (weight for length and height for less than 3 SD for mean as per WHO growth charts) \-

Design outcomes

Primary

MeasureTime frameDescription
Proportion of children who achieved spasm freedom as per parental reports in both the groups6 weeksThe proportion of children who achieve spasm freedom defined as no witnessed spasms on and between day 14 and day 42 as per parental reports will be evaluated in the both the groups

Secondary

MeasureTime frameDescription
Number of days after initiation of trial treatment on which spasms were not seen and after which response was maintained until 6 weeks (day 42) of treatment in both the groups6 weeksNumber of days after initiation of trial treatment on which spasms were not seen and after which response was maintained until 6 weeks (day 42) of treatment in both the groups
Proportion of children who achieve resolution of hypsarrhythmia on electro encephalogram at 2 weeks (in all cases) and at 6 weeks (for cases with sustained clinical response) in both the groups.6 weeksProportion of children who achieve resolution of hypsarrhythmia on electro encephalogram at 2 weeks (in all cases) and at 6 weeks (for cases with sustained clinical response) in both the groups.
Description and proportion of the adverse effects of methylprednisolone in the experimental group6 weeksDescription and proportion of the adverse effects of methylprednisolone in the experimental group

Countries

India

Contacts

Primary ContactDipti Kapoor, MD
diptikumar81@yahoo.co.in91-9818426830
Backup ContactSuvasini Sharma, MD, DM
sharma.suvasini@gmail.com91-9910234344

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026